It is currently being developed by AstraZeneca and Avillion in the US under the terms of an agreement signed in 2018. Researchers evaluated the time it took for patients to experience severe ...
UK biotech Avillion has reported positive mid-stage results with chronic psoriasis drug sonelokimab, which it is developing with Merck KGaA as an alternative to drugs like Novartis' Cosentyx.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback